Brock University Professor of Health Sciences Newman Sze, who is the Canada Research Chair in Mechanisms of Health and Disease, and his international team have discovered a groundbreaking immunotherapy method that could potentially add years to healthy aging.
A Brock-led international research team has discovered a groundbreaking immunotherapy method that could potentially add years to healthy aging.
The research, published in the journal EMBO Molecular Medicine, introduces an innovative method to address health issues arising from poor lifestyle choices, which can cause damage to biomolecules and contribute to the development of diseases later in life.
Professor of Health Sciences Newman Sze and his team developed an approach that involves directing the immune system to clear out accumulated proteins damaged by inactive lifestyles, unhealthy diets, various stresses and genetic factors, root causes of aging and age-related diseases.
“Age-related chronic diseases are a major health-care burden,” says Sze, the Canada Research Chair in Mechanisms of Health and Disease. “We therefore developed a first-of-its-kind monoclonal antibody drug that harnesses the immune system to target and remove these abnormal proteins, providing an effective treatment for age-related health problems.”
As time passes, environmental stresses and physiological conditions cause biomolecular damages in tissues. One of these changes, called isoDGR, triggers chronic inflammation in the body and leads to tissue degeneration.
Uncontrolled chronic inflammation, in turn, can lead to conditions such as cardiovascular disease, cancer, Type 2 diabetes, arthritis and Alzheimer’s disease.
While the accumulation of isoDGR has been identified as a ‘molecular clock’ of aging, the new research paper says potential benefits of targeting these structures with specific immunotherapies remain largely unknown.
Sze and his team created monoclonal antibodies called isoDGR-mAb. These lab-engineered proteins are designed to boost the immune system’s ability to attack unhealthy cells or abnormal molecules. Such immunotherapies are already being used to treat various cancers, autoimmune disorders and infectious diseases.
Using animal models, the team found that these lab-engineered molecules stimulated the immune system to clear out the proteins in tissues that had been damaged by isoDGR. Treatment with isoDGR-mAb not only doubled lifespan but also preserved behaviour and co-ordination functions and reduced pro-inflammatory cytokine levels in the circulation and body tissues.
Sze says the team’s findings could lead to the development of immunotherapy-based interventions to extend the healthy lifespan of humans.
“The existing treatments for age-related diseases primarily address symptoms,” says Sze. “Our pioneering mAb, uniquely focused on targeting the root causes of chronic diseases, is anticipated to substantially extend human health span.”
As Canada Research Chair, Sze studies diseases that occur as people age, specifically diseases related to the brain and the blood vessels becoming damaged. His lab has developed new research methods that investigate how body tissues deteriorate over time, and created new drugs to guide the immune system to eliminate abnormal biomolecules.
This latest paper, “Immunotherapy targeting isoDGR-protein damage extends lifespan in a mouse model of protein deamidation,” involved researchers from Brock as well as universities in Singapore, China, New Zealand and the United Kingdom.
The team’s Brock researchers include Health Sciences Professors Deborah O’Leary and Evangelia Tsiani, Health Sciences Associate Professors Adam MacNeil and Rebecca MacPherson, and graduate students Ranjith Iyappan, Evelin Melekh and SoFong Cam Ngan.
The Latest Updates from Bing News
Go deeper with Bing News on:
Monoclonal antibody drug
- Ono Pharma inks drug discovery collaboration with Epsilon Molecular Engineering aiming at the generation of novel VHH antibody drugs
Ono Pharmaceutical Co., Ltd., is one of the largest pharmaceutical companies in Japan, announced that it has entered into a drug discovery collaboration agreement with Epsilon Molecular Engineering, ...
- Chemomab’s first-in class monoclonal antibody for fibro-inflammatory diseases, CM-101 receives Brazilian & Israel patents
CM-101 has been granted Orphan Drug designation in the US and the EU and the FDA recently awarded CM-101 Fast Track designation for the treatment of PSC in adults. CM-101 is a monoclonal antibody that ...
- 'Switchable' bispecific antibodies pave way for safer cancer treatment
In the ever-evolving battle against cancer, immunotherapy presents a turning point. It began with harnessing the body's immune system to fight cancer, a concept rooted more than a century ago but only ...
- Vaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platform
(RTTNews) - Vaccinex, Inc. (VCNX) has entered into eight new antibody discovery agreements integrating use of its ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein ...
- Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Before this discovery, neutralizing antibodies were only able to target the tip of the ... rarely seen with existing drugs, neutralize the viruses and that this data correlated with in vitro and the ...
Go deeper with Bing News on:
- Vitamin D3 and phytochemicals team up for immune boost and aging defense, study finds
Chaphalkar, PhD.In a recent narrative review published in the International Journal of Molecular Sciences, researchers in Japan discussed the combined effects of vitamin D3 and phytochemicals in ...
- I’m a longevity expert — here are the best foods to eat for a long and healthy life
Here’s what the pros shop for — and if you want a long and healthy life, they say ... anti-cancer and anti-aging phytonutrients they contain. “There’s really no upper limit on how many cruciferous ...
- Home health care linked to increased hospice use at end-of-life, study reveals
the Hunterdon Professor of Nursing Research at the Rutgers School of Nursing and director of the Community Health and Aging Outcomes Laboratory within the Rutgers Institute for Health, Health Care ...
- Cycles of a diet that mimics fasting can reduce signs of immune system aging, as well as insulin resistance and liver fat
A recent study showed that three cycles of a fasting-mimicking diet in adults were associated with lower pre-diabetes markers, lower hepatic fat, and a higher lymphoid-to-myeloid ratio, which is an ...
- Hospital's Center for Healthy Aging offers seniors a new option
Nobody can turn back the clock. But Santa Fe's aging population shouldn't have to do it without access to comprehensive primary care tailored to their specific needs. That's the idea behind the ...